COMP <GO>
OMDA vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Omada Health Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: OMDA 2
— ABBV 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $19.65 (+2.45%) • MKT CAP: $1.20B
roic
-15.70%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OMDA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OMDA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.70% | 70.20% | -4.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -15.70% | 29.00% | -44.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.41% | 3.47% | -2.06 | ABBV | /fcf-yield <GO> |
| Operating Margin | -4.60% | 24.60% | -29.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 6.90% | -11.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 53.20% | 8.60% | +44.60 | OMDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.93 | 5.33 | +3.60 | OMDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.6 | 65.1 | -21.54 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.20B | $513.86B | -$512.66B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OMDA REV | ABBV REV | OMDA GROSS % | ABBV GROSS % | OMDA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $260.2M | $61.16B | 65.7% | 70.2% | $16.9M | $17.82B |
| FY 2024 | $169.8M | $56.33B | 60.6% | 70.0% | -$34.8M | $17.83B |
| FY 2023 | $122.8M | $54.32B | — | — | -$49.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OMDA // BETA —
ABBV // BETA 1.15